GrOwnValve Achieves Primary Safety Endpoint in First-in-Human Heart Valve Study

All five patients complete six-month follow-up without predefined prosthesis-related safety events BERLIN, Oct. 26, 2026 /PRNewswire/ -- GrOwnValve GmbH, a Berlin-based medical technology company developing personalized heart valves from patients' own tissue, today announced the...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.